Biomarkers in immunoglobulin light chain amyloidosis

J 2017

Biomarkers in immunoglobulin light chain amyloidosis

KUFOVA, Z., T. SEVCIKOVA, K. GROWKOVA, P. VOJTA, J. FILIPOVA et. al.

Základní údaje

Originální název

Biomarkers in immunoglobulin light chain amyloidosis

Autoři

KUFOVA, Z. (203 Česká republika), T. SEVCIKOVA (203 Česká republika), K. GROWKOVA (203 Česká republika), P. VOJTA (203 Česká republika), J. FILIPOVA (203 Česká republika), Zdeněk ADAM (203 Česká republika), Luděk POUR (203 Česká republika), Miroslav PENKA (203 Česká republika), R. RYSAVA (203 Česká republika), Pavel NĚMEC (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Petra VYCHYTILOVÁ (203 Česká republika, domácí), A. JURCZYSZYN (616 Polsko), S. GROSICKI (616 Polsko), A. BARCHNICKA (616 Polsko), M. HAJDUCH (203 Česká republika), M. SIMICEK (203 Česká republika) a R. HAJEK (203 Česká republika)

Vydání

Klinická onkologie, Praha, Ambit Media, 2017, 0862-495X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00098262

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.14735/amko20172S60

Klíčová slova anglicky

amyloidosis; genome; microRNA; plasma cell; transcriptome; immunoglobulin

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 3. 2018 16:50, Soňa Böhmová

Anotace

V originále

Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.

Citovat

KUFOVA, Z., T. SEVCIKOVA, K. GROWKOVA, P. VOJTA, J. FILIPOVA, Zdeněk ADAM, Luděk POUR, Miroslav PENKA, R. RYSAVA, Pavel NĚMEC, Lucie BROŽOVÁ, Petra VYCHYTILOVÁ, A. JURCZYSZYN, S. GROSICKI, A. BARCHNICKA, M. HAJDUCH, M. SIMICEK a R. HAJEK. Biomarkers in immunoglobulin light chain amyloidosis. Klinická onkologie. Praha: Ambit Media, 2017, roč. 30, Suppl. 2, s. "2S60"-"2S67", 8 s. ISSN 0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S60.

@article{1395504,
   author = {Kufova, Z. and Sevcikova, T. and Growkova, K. and Vojta, P. and Filipova, J. and Adam, Zdeněk and Pour, Luděk and Penka, Miroslav and Rysava, R. and Němec, Pavel and Brožová, Lucie and Vychytilová, Petra and Jurczyszyn, A. and Grosicki, S. and Barchnicka, A. and Hajduch, M. and Simicek, M. and Hajek, R.},
   article_location = {Praha},
   article_number = {Suppl. 2},
   doi = {http://dx.doi.org/10.14735/amko20172S60},
   keywords = {amyloidosis; genome; microRNA; plasma cell; transcriptome; immunoglobulin},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinická onkologie},
   title = {Biomarkers in immunoglobulin light chain amyloidosis},
   volume = {30},
   year = {2017}
}

TY  - JOUR
ID  - 1395504
AU  - Kufova, Z. - Sevcikova, T. - Growkova, K. - Vojta, P. - Filipova, J. - Adam, Zdeněk - Pour, Luděk - Penka, Miroslav - Rysava, R. - Němec, Pavel - Brožová, Lucie - Vychytilová, Petra - Jurczyszyn, A. - Grosicki, S. - Barchnicka, A. - Hajduch, M. - Simicek, M. - Hajek, R.
PY  - 2017
TI  - Biomarkers in immunoglobulin light chain amyloidosis
JF  - Klinická onkologie
VL  - 30
IS  - Suppl. 2
SP  - "2S60"-"2S67"
EP  - "2S60"-"2S67"
PB  - Ambit Media
SN  - 0862495X
KW  - amyloidosis
KW  - genome
KW  - microRNA
KW  - plasma cell
KW  - transcriptome
KW  - immunoglobulin
N2  - Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.
ER  -

KUFOVA, Z., T. SEVCIKOVA, K. GROWKOVA, P. VOJTA, J. FILIPOVA, Zdeněk ADAM, Luděk POUR, Miroslav PENKA, R. RYSAVA, Pavel NĚMEC, Lucie BROŽOVÁ, Petra VYCHYTILOVÁ, A. JURCZYSZYN, S. GROSICKI, A. BARCHNICKA, M. HAJDUCH, M. SIMICEK a R. HAJEK. Biomarkers in immunoglobulin light chain amyloidosis. \textit{Klinická onkologie}. Praha: Ambit Media, 2017, roč.~30, Suppl. 2, s.~''2S60''-''2S67'', 8 s. ISSN~0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S60.

Podrobný výpis o publikaci